Adhera Therapeutics Stock Beta
| ATRXDelisted Stock | USD 0.72 0.00 0.00% |
Adhera Therapeutics fundamentals help investors to digest information that contributes to Adhera Therapeutics' financial success or failures. It also enables traders to predict the movement of Adhera Pink Sheet. The fundamental analysis module provides a way to measure Adhera Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adhera Therapeutics pink sheet.
Adhera |
Adhera Therapeutics Company Beta Analysis
Adhera Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Adhera Therapeutics Beta | -0.14 |
Most of Adhera Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adhera Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Adhera Therapeutics has a Beta of -0.1416. This is 116.47% lower than that of the Biotechnology sector and 110.19% lower than that of the Health Care industry. The beta for all United States stocks is 5.6% lower than that of the firm.
Adhera Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adhera Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Adhera Therapeutics could also be used in its relative valuation, which is a method of valuing Adhera Therapeutics by comparing valuation metrics of similar companies.Adhera Therapeutics is currently under evaluation in beta category among its peers.
As returns on the market increase, returns on owning Adhera Therapeutics are expected to decrease at a much lower rate. During the bear market, Adhera Therapeutics is likely to outperform the market.
Adhera Fundamentals
| Return On Asset | -4.48 | ||||
| Current Valuation | 10.55 M | ||||
| Shares Outstanding | 3.16 M | ||||
| Shares Owned By Insiders | 21.87 % | ||||
| Number Of Shares Shorted | 2.05 K | ||||
| Price To Earning | (125.83) X | ||||
| Price To Sales | 8.23 X | ||||
| Gross Profit | (157 K) | ||||
| EBITDA | (4.92 M) | ||||
| Net Income | (6.35 M) | ||||
| Cash And Equivalents | 849 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 7.35 M | ||||
| Debt To Equity | 56.30 % | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (6.90) X | ||||
| Cash Flow From Operations | (665 K) | ||||
| Short Ratio | 3.24 X | ||||
| Earnings Per Share | (0.52) X | ||||
| Number Of Employees | 12 | ||||
| Beta | -0.14 | ||||
| Market Capitalization | 2.18 M | ||||
| Total Asset | 196 K | ||||
| Retained Earnings | (42.43 M) | ||||
| Working Capital | 16.49 M | ||||
| Current Asset | 20.36 M | ||||
| Current Liabilities | 3.88 M | ||||
| Net Asset | 196 K |
About Adhera Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adhera Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adhera Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adhera Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Adhera Pink Sheet
If you are still planning to invest in Adhera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adhera Therapeutics' history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |